A novel peptide 'T14' reflects age and photo-aging in human skin.


Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
28 06 2023
Historique:
received: 23 01 2023
accepted: 09 06 2023
medline: 7 7 2023
pubmed: 29 6 2023
entrez: 29 6 2023
Statut: ppublish

Résumé

T14 is a 14mer peptide derived from the C-terminus of acetylcholinesterase (AChE). Once cleaved, it is independently bioactive of the parent molecule and enhances calcium influx in different cell types, in a range of scenarios: it binds to an allosteric site selectively on the alpha-7 receptor, where it modulates calcium influx and is thus a potential trophic agent, as already reported in a range of normal developmental scenarios. However, if inappropriately activated, this erstwhile beneficial effect converts to a toxic one, resulting in pathologies as disparate as Alzheimer's and various metastatic cancers. Given that epidermal keratinocyte cells have the same ectodermal origin as brain cells, as well as expressing AChE and the alpha-7 receptor, we have explored whether T14 plays a comparable role. Here we report that the T14 immunoreactivity is detectable in human keratinocytes with levels inversely related to age: this decrease is even more apparent with chronic photo-exposure and thus accelerated skin aging. We conclude that T14, an agent promoting cell growth and renewal in other parts of the body, also operates in skin, Moreover, monitoring of keratinocyte T14 levels might offer further insights into the now well reported link between degenerative diseases and epidermal cell profile.

Identifiants

pubmed: 37382595
pii: 204844
doi: 10.18632/aging.204844
pmc: PMC10333063
doi:

Substances chimiques

Acetylcholinesterase EC 3.1.1.7
Peptide Fragments 0
Calcium SY7Q814VUP
Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5279-5289

Références

Br J Dermatol. 2015;172(5):1338-45
pubmed: 25627783
J Invest Dermatol. 2010 Feb;130(2):604-8
pubmed: 19776755
J Alzheimers Dis. 2014;38(3):633-46
pubmed: 24047617
J Invest Dermatol. 1993 Jul;101(1):32-6
pubmed: 8331294
J Cell Physiol. 2008 Apr;215(1):82-100
pubmed: 17948252
J Biol Chem. 2018 Sep 14;293(37):14417-14428
pubmed: 30076217
J Neurochem. 2004 Jul;90(2):325-31
pubmed: 15228589
Eur J Cell Biol. 2000 Dec;79(12):905-14
pubmed: 11152291
Neurosci Lett. 2004 Apr 1;358(3):210-4
pubmed: 15039118
Neurosci Lett. 1996 Aug 9;213(3):201-4
pubmed: 8873149
Eur J Neurosci. 1997 Dec;9(12):2734-42
pubmed: 9517478
Neurochem Int. 2020 Dec;141:104861
pubmed: 33038610
Chem Biol Interact. 2013 May 25;203(3):543-6
pubmed: 23562497
Int J Biochem Cell Biol. 2022 Aug;149:106260
pubmed: 35781081
Neuropharmacology. 2016 Jun;105:47-60
pubmed: 26773199
FASEB J. 2020 Jul;34(7):8941-8958
pubmed: 32519787
PLoS One. 2020 Mar 23;15(3):e0229819
pubmed: 32203525
Neuroscience. 2002;111(3):649-56
pubmed: 12031351
Mov Disord Clin Pract. 2016 Sep 08;4(1):21-31
pubmed: 30363435
Oncotarget. 2017 Apr 4;8(14):22307-22308
pubmed: 28423607
J Am Acad Dermatol. 2018 Jan;78(1):29-39.e7
pubmed: 29146147
J Eur Acad Dermatol Venereol. 2011 Aug;25(8):873-84
pubmed: 21261751
Arch Dermatol. 2002 Nov;138(11):1462-70
pubmed: 12437452
Neuropharmacology. 2016 Jun;105:487-499
pubmed: 26867503
Alzheimers Dement (N Y). 2022 Apr 05;8(1):e12274
pubmed: 35415206
Chem Biol Interact. 2005 Dec 15;157-158:211-8
pubmed: 16297900
Exp Brain Res. 2004 Apr;155(4):500-8
pubmed: 14685807
Sci Rep. 2020 Apr 15;10(1):6454
pubmed: 32296117
J Cell Biol. 2002 Oct 28;159(2):325-36
pubmed: 12391028
J Biol Chem. 1991 Dec 5;266(34):23083-90
pubmed: 1744105
Oncotarget. 2017 Feb 14;8(7):11414-11424
pubmed: 28077796
J Cell Commun Signal. 2022 Sep;16(3):421-432
pubmed: 35060094
PLoS One. 2009;4(3):e4846
pubmed: 19287501
PLoS One. 2012;7(11):e50393
pubmed: 23226273
Neurodegener Dis Manag. 2015 Dec;5(6):465-7
pubmed: 26619251
Anal Quant Cytol Histol. 1993 Apr;15(2):75-82
pubmed: 8318130
PLoS One. 2013;8(2):e54864
pubmed: 23390503
Lancet. 1992 Jan 25;339(8787):245
pubmed: 1346198
J Cell Biol. 2004 Jul 19;166(2):261-72
pubmed: 15263021
Ann N Y Acad Sci. 2007 Nov;1119:40-50
pubmed: 18056953
Eur J Neurosci. 2003 May;17(9):1991-5
pubmed: 12752800
Front Aging Neurosci. 2020 Oct 22;12:570992
pubmed: 33192461
Clin Interv Aging. 2020 Jun 17;15:897-905
pubmed: 32606631

Auteurs

Sheila Rocha (S)

Unilever Research and Development, Trumbull, CT 06611, USA.

Sara Garcia Ratés (SG)

Neuro-Bio Ltd, Culham Science Center, Abingdon, Oxfordshire OX14 3DB, UK.

Tumisang Moswete (T)

Neuro-Bio Ltd, Culham Science Center, Abingdon, Oxfordshire OX14 3DB, UK.

Kristopher Kalleberg (K)

Unilever Research and Development, Trumbull, CT 06611, USA.

Anna Villa (A)

Unilever Research and Development, Trumbull, CT 06611, USA.

Jason P Harcup (JP)

Unilever Research and Development, Trumbull, CT 06611, USA.

Susan A Greenfield (SA)

Neuro-Bio Ltd, Culham Science Center, Abingdon, Oxfordshire OX14 3DB, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH